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Abstract
Background—Experimental evidence has demonstrated an anti-neoplastic role for vitamin D in
the colon and higher circulating 25-hydroxyvitamin D (25[OH]D) levels are consistently
associated with a lower risk of colorectal cancer (CRC). Genome-wide association studies have
identified loci associated with levels of circulating 25(OH)D. The identified SNPs from four gene
regions, collectively explain approximately 5% of the variance in circulating 25(OH)D.
Methods—We investigated whether six polymorphisms in GC, CYP2R1, CYP24A1 and
DHCR7/NADSYN1, genes previously shown to be associated with circulating 25(OH)D levels,
were associated with CRC risk in 10,061 cases and 12,768 controls drawn from 13 studies
included in the Genetics and Epidemiology of Colorectal Cancer Consortium (GECCO) and Colon
Cancer Family Registry (CCFR). We performed a meta-analysis of crude and multivariate-
adjusted logistic regression models to calculate odds ratios and associated confidence intervals for
SNPs individually, SNPs simultaneously, and for a vitamin D additive genetic risk score (GRS).
Results—We did not observe a statistically significant association between the 25(OH)D
associated SNPs and CRC marginally, conditionally, or as a GRS, or for colon or rectal cancer
separately or combined.
Conclusions—Our findings do not support an association between SNPs associated with
circulating 25(OH)D and risk of CRC. Additional work is warranted to investigate the complex
relationship between 25(OH)D and CRC risk.
Impact—There was no association observed between genetic markers of circulating 25(OH)D
and CRC. These genetic markers account for a small proportion of the variance in 25(OH)D.
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Colorectal cancer (CRC) is the second leading cause of cancer death in men and women in
the United States. It is estimated that in 2012, a total of 143,460 U.S. men and women will
be diagnosed with cancer of the colon and rectum(1). Family history is a strong risk factor
for colorectal cancer(2, 3), which is consistent with the existence of shared etiologic and
genetic determinants among relatives. Known genetic mutations account for about 30-50%
of the familial risk(4); much of the remaining familial aggregation is unexplained. Genome-
wide association studies (GWAS) of sporadic CRC have identified at least 20 independent
loci statistically significantly associated with risk (5-12). However, these variants
cumulatively explain only a very small fraction of CRC risk (13).
Beyond inherited risk, there is a large body of evidence supporting the role of non-genetic
factors, including vitamin D status, in the etiology of CRC. The first human evidence to
suggest an association between vitamin D and CRC was the ecologic study by Garland and
Garland based on data collected in the 1950's and 60's which showed a strong inverse
association between colon cancer mortality and solar ultraviolet B (UVB) radiation exposure
in the U.S. (14). Since then, most but not all case-control and cohort studies have found an
inverse association between intake of vitamin D (both diet and supplements) and CRC risk
(15-18), with even stronger associations observed using directly measured circulating
25(OH)D (19-22), an integrated biomarker of vitamin D status (23). Randomized clinical
trials of vitamin D supplementation, including the Women's Health Initiative(24) and the
British Oxford Trial(25), have not demonstrated reductions in colorectal cancer incidence.
However, these trials have generally tested low doses of vitamin D and each included less
than seven years of follow-up, which is likely insufficient to shown an effect on cancer
incidence, particularly in light of the long latency of disease. Similarly, large meta-analyses
of clinical trials have not shown robust evidence for a protective role of vitamin D in the
development of colorectal cancer(26) despite some indication of a preventative role in the
development of adenomas(27).
Circulating 25(OH)D levels are a function of dietary sources and exposure of the skin to
sunlight, specifically UVB rays. In addition to environmental determinants, twin and family
studies suggest that genetic factors contribute substantially to circulating vitamin D levels,
with heritability estimates ranging from 43 to 80% (28-31).
Two published GWAS of 25(OH)D have uncovered SNPs significantly associated with
lower circulating 25(OH)D levels in four gene regions that appear to have functional
relevance:GC (group-specific component vitamin D binding protein); CYP2R1 (cytochrome
P450, family 2, subfamily R, polypeptide 1, encoding C-25 hydroxylase that converts
vitamin D to the active ligand for the vitamin D receptor; DHCR7/NADSYN1 (7-
dehydrocholesterol [7-DHC] reductase/nicotinamide adenine dinucleotide synthetase(32))
with roles in the synthetic vitamin D pathway(33, 34); and CYP24A1 (encoding 24-
hydroxylase involved in the degradation of both 25-hydroxyvitamin D and 1,25-
dihydroxyvitamin D) (33, 34). Both the GC SNP rs2282679 and the DHCR7/NADSYN1
SNPs are located in intronic regions, with the GC SNP demonstrating the largest magnitude
of association with 25(OH)D <75 nmol/L (OR 1.63 (1.53–1.73)(34). The SNP rs10741657
is proximal to the CYP2R1 gene and rs6013897 is proximal to CYP24A1 yet the precise
associations with gene expression are yet to be determined.
We investigated the association between these SNPs previously identified as associated with
25(OH)D, and risk of CRC in 13 cohorts that are part of the Genetics and Epidemiology of
Colorectal Cancer Consortium (GECCO) and the Colon Cancer Family Registry (CCFR).
Within a subset of participants from NHS, HPFS and PHS with measured pre-diagnostic
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plasma 25(OH)D levels, we also examined the joint effects of plasma 25(OH)D and
25(OH)D-associated SNPs on CRC risk.
Materials and Methods
Study Population
The analysis included a total of 10,061 cases and 12,768 controls of European ancestry
drawn from 13 studies within GECCO and CCFR. Details on the studies are provided in
Table 1, and are described in detail in the Supplemental Note and Supplemental Table 1. In
brief, each study defined CRC cases as colorectal adenocarcinoma, confirmed by medical
records, pathologic reports, or death certificates. All participants provided informed consent
and studies were approved by their respective Institutional Review Boards. None of the
studies included in GECCO or CCFR contributed subjects to the any previous GWAS of
25(OH)D with the exception of a subset of the NHS subjects (n=1,342) who participated in
the validation stage of one study (33).
Genotyping, Quality Assurance/Quality Control and Imputation
We used genotype data from GECCO and CCFR. GECCO consisted of participants within
the French Association Study Evaluating RISK for sporadic colorectal cancer (ASTERISK);
Hawaii Colorectal Cancer Studies 2 and 3 (Colo2&3); Darmkrebs: Chancen der Verhütung
durch Screening (DACHS); Diet, Activity, and Lifestyle Study (DALS); Health
Professionals Follow-up Study (HPFS); Multiethnic Cohort (MEC); Nurses' Health Study
(NHS); Ontario Familial Colorectal Cancer Registry (OFCCR); Physician's Health Study
(PHS); Prostate, Lung, Colorectal Cancer, and Ovarian Cancer Screening Trial (PLCO);
VITamins And Lifestyle (VITAL); and the Women's Health Initiative (WHI). Phase-one
genotyping on a total of 1,709 colon cancer cases and 4,214 controls from PLCO, WHI, and
DALS (PLCO Set 1, WHI Set 1, and DALS Set 1) was done using Illumina HumanHap
550K, 610K, or combined Illumina 300K and 240K, and has been described previously (12).
A total of 650 CRC cases and 522 controls from OFCCR are included in GECCO from
previous genotyping using Affymetrix platforms (35). A total of 5,540 CRC cases and 5,425
controls from ASTERISK, Colo2&3, DACHS, DALS Set 2, MEC, PMH, PLCO Set 2,
VITAL, and WHI Set 2 were successfully genotyped using Illumina HumanCytoSNP. A
total of 2,004 CRC cases and 2,244 controls from HPFS (2 sets), NHS (2 sets), and PHS (2
sets) were successfully genotyped using Illumina HumanOmniExpress. The CCFR included
a population-based case-control set of participants from sites in USA, Canada, and Australia
successfully genotyped using Illumina Human1M or Human1M-Duo (36).
DNA was extracted from samples of white blood cells or, in the case of a subset of NHS,
HPFS, DACHS, MEC, and PLCO samples, and all VITAL samples from buccal cells using
conventional methods(37). All studies included 1 to 6% blinded duplicates to monitor
quality of the genotyping. All individual-level genotype data were managed centrally at
University of Southern California (CCFR), the Ontario Institute for Cancer Research
(OFCCR), the University of Washington (HPFS, NHS, and PHS), or the GECCO and CCFR
Coordinating Center (CC) at the Fred Hutchinson Cancer Research Center (all other studies)
to ensure consistent quality assurance and quality control (QA/QC) and statistical analysis.
Details on the QA/QC can be found in Supplemental Table 2. In brief, samples were
excluded based on call rate, heterozygosity, unexpected duplicates, gender discrepancy, and
unexpectedly high identity-by-descent or unexpected concordance (> 65%) with another
individual. For missing SNP data, all GECCO studies were imputed to HapMap II release
24, with the exception of OFCCR, which was imputed to HapMap II release 22. CCFR was
imputed using IMPUTE (38), OFCCR was imputed using BEAGLE (39), and all other
studies were imputed using MACH (40). All SNPs met quality-control measures for Hardy
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Weinberg Equilibrium in controls (HWE, p ≥ 10-4), and minor allele frequency (MAF ≥
1%)or imputation R2 > 0.3.
Dietary and Lifestyle Factors
Dietary information, including calcium, folate, fiber and alcohol intake, was available for
Colo2&3, DALS, HPFS, MEC, NHS, PLCO I, PLCO II, VITAL, WHI; calcium, folate and
alcohol was available in PHS; and calcium and alcohol in ASTERISK and DACHS. Regular
use of non-steroidal anti-inflammatory drugs (NSAIDs) was available for CCFR, Colo2&3,
DACHS, HPFS, MEC, NHS and VITAL. All studies collected data on smoking status, red
meat consumption, physical activity, body mass index, and hormone replacement therapy in
post-menopausal women with the exception of ASTERISK. ASTERISK was restricted to
cases with no family history of colorectal cancer. We adopted a flexible approach to
retrospective covariate harmonization as previously described (41, 42).
Laboratory Assessment of 25(OH)D
In previous studies, we measured plasma levels of 25(OH)D in a subset of the cases and
controls with genetic data that were nested within the NHS, HPFS, and PHS (total cases
n=672 and total controls n=909) using a radioimmunosorbent assay in the laboratory of Dr.
Bruce W. Hollis (Medical University of South Carolina, Charleston, SC). The median intra-
assay coefficient of variation from blinded quality-control samples was 11.8% in NHS,
10.1% in HPFS, and 13.8% in PHS. Cases and their controls were analyzed in the same
batch, and laboratory personnel were blinded to case, control, and quality-control status (21,
43, 44).
Statistical Analyses
The statistical analyses of the GECCO and CCFR samples were conducted at a central data
analysis center on individual-level data to ensure a consistent analytical approach. For each
study, we estimated the association between each SNP and risk for CRC by calculating
betas, odds ratios (ORs), standard errors, 95% confidence intervals (CIs), and p-values using
log-additive genetic models relating the genotype dose (0, 1 or 2 copies of the allele) to risk
of CRC. For imputed SNPs, we used the dosage (expected number of copies of the minor
allele) when testing associations, which has been shown to give unbiased estimates (45). We
also created a genetic risk score (GRS), comprised of four SNPs from four distinct gene
regions to ensure no single gene was over represented in the score using an allelic scoring
system based on summing the number of risk alleles (previously associated with lower
25(OH)D), yielding a possible range of 0-8 alleles to derive estimates of allelic OR.
Minimally adjusted models included covariates for age, sex (when appropriate), center
(when appropriate), smoking status, batch effects (ASTERISK only), and the first three
principal components from EIGENSTRAT to account for population substructure.
Multivariate models were additionally adjusted for family history of CRC, BMI, NSAID
use, alcohol use, dietary calcium, folate and red meat intake, sedentary status, and hormone
replacement therapy based on covariate availability. We repeated the minimally adjusted
model analyses stratified by anatomical site (colon and rectum).
We conducted inverse-variance weighted, fixed-effects meta-analysis to combine beta
estimates and standard errors from log-additive models across individual studies. We chose
to focus on fixed-effects to improve power and assessed heterogeneity across studies
utilizing random effects models (46).
For analyses of the joint effect of plasma 25(OH)D and our GRS comprised of 25(OH)D-
associated SNPs, we included the 672 cases and 909 controls in NHS, HPFS, and PHS
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among whom we had previously measured pre-diagnostic levels of 25(OH)D and also had
genotype data (21, 44). We calculated ORs and 95% CI for CRC comparing extreme
quartiles of 25(OH)D defined according to cohort-specific cutpoints determined by the
distribution in controls (44). We compared the GRS-associated risk for CRC across
categories of high versus low vitamin D levels and quartiles of vitamin D, as well as tested
for multiplicative interactions between GRS and a 1ng/mL increase in 25(OH)D and high/
low vitamin D using a product term in the model and assessing its significance by the Wald
method.
We used PLINK, R (47, 48) and SAS 9.2 (SAS Institute Inc, Cary, NC) to conduct the
statistical analyses. We estimated our power to detect an association between a GRS and
CRC using the method of Tosteson et al. (49). These calculations account for the strength of
association between the vitamin D SNPs and circulating 25(OH)D.
Results
Our study included 10,061 CRC cases and 12,768 controls. Overall 53% were female, and
the mean age at CRC diagnosis was 64.0 years (+/- 9.6 SD), 55.0% past/current smokers and
with risk allele frequencies ranging from 16 – 61%. Table 1 summarizes the characteristics
of the studies included in the analyses. Analyses of each individual SNP in models first
minimally and then fully adjusted, did not demonstrate a statistically significant association
with CRC risk (Table 2). In analyses stratified by anatomic site each of the four SNP
associations remained non-significant (Table 3), in tests of associations with cancers of the
colon and rectum.
We considered the possibility that a combination of SNPs associated with circulating
25(OH)D in prior GWAS may be associated with risk of CRC. However, an analysis of a
GRS comprised of the risk alleles from the four SNPs associated with plasma 25(OH)D and
CRC risk did not demonstrate any significant association (Table 4). The figure 1 forest plot
depicts the ORs and 95% CIs of the GRS and CRC association of the individual GECCO
and CCFR studies showing a balanced distribution of study-specific odds ratios around the
null value of 1.0.
Among the subset of NHS, HPFS and PHS subjects with measured prediagnostic plasma
25(OH)D levels (N=672 cases and N=909 controls), we observed that a 1 allele change in
our GRS was associated with a mean 1.5ng/mL decrease in 25(OH)D (p-value <0.0001).
Compared with the lowest quartile of 25(OH)D, the highest quartile of 25(OH)D was
associated with an OR of 0.66 (95% CI 0.47, 0.92) for CRC. We did not observe a
differential association of GRS with risk of CRC according to strata of quartile levels of
plasma 25(OH)D or according to high or low levels of 25(OH)D (p-heterogeneity>0.05).
Discussion
Consistent evidence from epidemiologic studies supports an inverse association between
circulating 25(OH)D, the best integrated biomarker of vitamin D status, and risk of CRC.
However, contrary to expectation, we did not observe a statistically significant association
between SNPs associated with circulating 25(OH)D and CRC, marginally or in an additive
GRS.
A number of epidemiologic studies have reported inverse associations between 25(OH)D
and CRC. A meta-analysis of five nested case–control studies reported a pooled odds ratio
of 0.49 (95% CI; 0.35– 0.68) for CRC comparing the highest quintile (median 37 ng/mL) of
25(OH)D with the lowest (6 ng/mL) (19). Another recent systematic review of nine studies
observed pooled RRs for CRC of 0.67 (95% CI, 0.54 to 0.80) comparing extreme quintiles
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of 25(OH)D (22). Overall, the estimated OR of CRC for a 10ng/mL increase in circulating
25(OH)D was 0.74 (95% CI, 0.63 to 0.89)with the relationship appearing approximately
linear (22). Several mechanisms could explain an anti-cancer benefit for vitamin D:
reduction of cell proliferation; inhibition of angiogenesis; promotion of cell differentiation;
and stimulation of apoptosis (23, 50-57). Vitamin D also has an anti-inflammatory effect,
reducing PTGS-2(COX-2) expression and decreasing levels of the inflammatory marker C-
reactive protein (58-60).
Prior clinical trials testing the association between vitamin D and cancer have been null. In a
5-year British placebo-controlled trial with cancer assessed as a secondary outcome, 100,000
IU of vitamin D3 every four months over five years was not associated with CRC incidence
(RR=1.02, 95% CI 0.60-1.74)(25). Similarly, among 36,000 women in the WHI calcium-
vitamin D trial, a combination of calcium (1000 mg/day) plus low-dose vitamin D3 (400 IU/
d) for a mean of 7 years did not reduce CRC incidence (RR=1.08, 95% CI 0.86-1.34)(24).
However, the interpretation of these null results is tempered by several important
limitations. First, the relatively low doses of vitamin D used were probably inadequate to
yield a substantial contrast between the treatment and placebo groups. Second, the duration
of follow-up was probably too short to observe an influence on incidence of cancer.
Observational data suggest that any influence of calcium and vitamin D intake on CRC risk
could require at least 10 years to emerge, consistent with our understanding of the prolonged
dwell time of the adenoma-carcinoma pathway(18). On the other hand, a Nebraska
population- based placebo-controlled trial of calcium alone or calcium plus vitamin D3
(1100 IU/d) observed a significantly lower cancer incidence among those supplemented with
calcium and vitamin D over just four years of treatment (61). However, follow-up of total
cancers was a secondary outcome and there were only a small number of CRC cases,
limiting the interpretation of these results.
Over 90% of circulating 25(OH)D is protein-bound with the GC encoded vitamin D binding
protein being the major carrier of 25(OH)D. Less than 1% of vitamin D circulates in its
unbound form (62). Vitamin D binding protein is a multifunctional protein that also binds
fatty acids, and may have immune functions independent of its role as a carrier of vitamin
D(63). Prior studies have observed that unbound 25(OH)D was more strongly related to
bone mineral density(64), parathyroid hormone levels among hemodialized patients(65),
than total 25(OH)D, thereby implicating a role for vitamin D binding protein in modifying
the biologic activity of circulating vitamin D. The available estimates of the association
between 25(OH)D and CRC, as well as genetic markers of 25(OH)D, are based solely on
total circulating 25(OH)D levels (19, 22, 33, 34). It is unclear how these estimates might
change when accounting for vitamin D binding protein levels or by individually examining
free and protein-bound 25(OH)D.
Prior studies have examined individual SNPs in CYP24A1 or GC(66, 67) in association with
risk of CRC. A prior DALS multicenter population-based case-control study of 1,600 CRC
cases found a statistically significant association between one CYP24A1 polymorphism and
overall risk of colon cancer, particularly for proximal colon cancer, as well as an association
between three CYP24A1 polymorphisms and distal colon cancer (67). However, the
correlation between these CYP24A1 genetic markers investigated by the DALS study and
the CYP24A1 marker examined in this full combined analysis study is very low (r2 <0.1).
Because our a priori hypothesis was that SNPs most strongly associated with 25(OH)D
levels would be associated with CRC, we did not consider total genetic variation in
CYP24A1 with CRC risk. It is possible that alternative CYP24A1 SNPs may be associated
with CRC through mechanisms independent of 25(OH) D levels. A prior study of the CCFR
cohort of 1,750 sibships found no evidence for associations between GC and the risk of
CRC, and no evidence for modification of the association by calcium and/or vitamin D
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intake (66). Studies of additional genes that are not significantly associated with circulating
25(OH)D but are implicated in the vitamin D pathway, including the vitamin D receptor
(VDR) SNPs Fok1 and BsmI, have yielded inconsistent results (68-71). Notably, among
over 10,000 men with prostate cancer, a greater number of low 25(OH)D SNPs were
associated with a decreased risk of aggressive prostate cancer (OR 0.66; 95% CI, 0.44-0.98
for 6–8 vs. 0–1 alleles,; Ptrend = 0.003)(72).
The lack of association that we observed between genetic markers associated with
circulating 25(OH)D and CRC is consistent with prior clinical trials of vitamin D and CRC
and would, at least initially, seem to argue against a causal association between vitamin D
and CRC(73). However, prior work has demonstrated that these 4 SNPs, though correlated
with circulating 25(OH)D, explain only a small fraction (5%) of the variance in circulating
25(OH)(74). Recently, a Scottish case-control study observed a significant association
between direct plasma measurements of 25(OH)D and CRC risk, yet failed to replicate the
association using an instrumental-variable method of mendelian randomization (MR) with
the same four genome-wide significant risk loci examined in our analysis (75). The
investigators attributed these inconsistent results to a presumed weak correlation between
these SNPs and 25(OH)D, as well as a limited sample size of 2,001 cases of CRC and 2,237
controls. Given our significantly larger sample size of approximately 10,000 cases and
12,500 controls and assuming a correlation between our GRS and 25(OH)D of r=0.17, with
a 10 ng/ml increase in 25(OH)D associated with OR=0.74 for CRC(22), our power to detect
a 1-allele change in our GRS is 96% (significance level of 0.05). However, if the true
magnitude of association with a 10ng/mL increase in 25(OH)D is in fact an OR of 0.85 for
CRC, we would have only had 56% power to detect a 1-allele change in our GRS.
We are not certain of the precise pathway or biological mediators by which 25(OH)D
influences CRC risk. Our GRS assumes that each included SNP would be associated with
increased CRC risk according to their observed association with lower 25(OH)D. If this
assumption is invalid, combining the alleles into this GRS would reduce our power to detect
associations with CRC. If we remove the GC SNP and repeat our power calculation, our
observed correlation between our GRS and 25(OH)D becomes r=0.11, resulting in
68%power to detect a 1 allele change in our proxy score.
We acknowledge some limitations. First, our study includes only populations of European
descent, which limits the generalizability of our findings. However, the circulating 25(OH)D
SNPs that we examined were identified in GWAS of populations of European descent, and
so the underlying genetic associations should hold in our study population. Moreover,
limiting our analysis to European descent populations minimizes the potential for
confounding by population structure. Second, if these SNPs are correlated with another
locus that influences the risk of CRC, this could confound our results(73). Third, despite our
large sample size, we had limited power to detect associations between individual SNPs and
risk of CRC.
In conclusion, our findings do not support an association between SNPs associated with
circulating 25(OH)D and risk of CRC. This may be due to the fact that these SNPs account
for only a small portion of the variance observed in circulating 25(OH)D levels and that
those alleles associated with low circulating levels of 25(OH)D may not affect CRC risk in
the same direction. Future studies are needed to examine the role of unbound and protein-
bound 25(OH)D, along with other biomarkers of the vitamin D pathway, in the development
of CRC.
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Figure 1. Forest plot of the genetic risk score and CRC for individual studies and meta-analysis
of all studies (allelic OR, 95% CI)
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